Stay updated with breaking news from Junshi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.
Sub: Transcript of the Earnings call conducted on May 10, 2023 Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015, please find enclosed the... | May 16, 2023
SHANGHAI, China, May 07, 2023 -- Shanghai Junshi Biosciences Co., Ltd announced a collaboration with Dr. Reddy’s Laboratories Limited to develop and commercialize toripalimab, the anti-PD-1... | May 7, 2023
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced a...
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited ("Dr.